Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06618287 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
A Phase 1 study of Breast Cancer and Lung Cancer, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 416
- Enrollment target
- 20
- Study locations
NCT06618287: Recruiting Phase 1 study of Breast Cancer and Lung Cancer, sponsored by Bristol-Myers Squibb.
NCT06618287 is a Phase 1 study of Breast Cancer and Lung Cancer that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 416 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06618287, a Phase 1 study of Breast Cancer and Lung Cancer, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 416 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Osimertinib
- DRUG Nivolumab
- DRUG Pumitamig
- DRUG BMS-986507
Study Locations (20)
Ohio
- Cleveland Clinic - Cleveland
- Local Institution - 0102 - Columbus
Oregon
- Local Institution - 0052 - Portland
- Local Institution - 0090 - Portland
Ontario
- Local Institution - 0064 - Newmarket
- Local Institution - 0023 - Ottawa
Alabama
- University of Alabama at Birmingham - Birmingham
Florida
- University of Miami Hospital and Clinics, Sylvester Cancer Center - Miami
Illinois
- Local Institution - 0125 - Maywood
Iowa
- Local Institution - 0065 - Iowa City
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 416 participants |
| Start Date | 2025-02-04 |
| Est. Completion | 2031-02-26 |
| Phase | Phase 1 |
What NCT06618287 shows while recruiting
NCT06618287 is an interventional study that assigns participants to a tested intervention. The registered 416 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06618287 names 20 study sites across 17 states, led by Ohio, Oregon, Ontario.
Frequently Asked Questions
What is clinical trial NCT06618287 about?
NCT06618287 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors". The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
What is the current status of trial NCT06618287?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 416 participants. The study started on 2025-02-04. Estimated completion is 2031-02-26.
What conditions does trial NCT06618287 study?
This clinical trial studies the following conditions: Breast Cancer, Lung Cancer.
What interventions are being tested in trial NCT06618287?
The interventions under investigation include: Pembrolizumab (DRUG), Osimertinib (DRUG), Nivolumab (DRUG), Pumitamig (DRUG), BMS-986507 (DRUG).
Who is sponsoring clinical trial NCT06618287?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06618287 being conducted?
This trial has 20 study locations across Alabama, Florida, Illinois, Iowa, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06618287's enrollment target sits among peer trials
416 224th of 1224 higher than 1,000 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03527537 · 416 participants · Phase 4
Gestational Diabetes and Pharmacotherapy (GAP)
- NCT05007782 · 416 participants · Phase 1
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
- NCT05520099 · 416 participants
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
- NCT06075745 · 416 participants · Phase 2
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI